Summary
Proteolysis occurs when proteinase activity exceeds inhibitor activity. Proteolysis is normally tightly regulated and is involved in cancer invasion and metastasis. The aim of this study was to compare proteolysis in breast and colorectal cancer. Proteinase and inhibitor expression were analysed in paired tumour and normal tissue samples from 43 breast and 24 colorectal cancer patients using substrate zymography, Western blotting and quenched fluorescence substrate hydrolysis. The expression of the latent forms of matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-9, urokinase plasminogen activator (uPA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression were observed in both tumour and normal tissue samples from breast and colorectal tissue; however, expression was greater in the tumour tissue. Expression of active MMP-2 and MMP-9 and the total MMP activity were greater in tumour compared to normal samples in both tissues (P< 0.05). The expression of all proteinases and total MMP activity was greater in colorectal tissue than breast tissue samples. Breast and colorectal cancer demonstrated different proteinase profiles, however proteolysis in both tissues was greater in tumour tissue than normal tissue.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baramova, E & Foidart, JM (1995). Matrix metalloproteinase family. Cell Biol Int 19: 239–242.
Barrett, AJ (1995). Classification of peptidases. Methods Enzymol 244: 1–15.
Bouchet, C, Spyratos, F, Martin, PM, Hacene, K, Gentile, A & Oglobine, J (1994). Prognostic value of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398–405.
Brown, CJ, Rahman, S, Morton, AC, Beauchamp, CL, Bramwell, H & Buttle, DJ (1996). Inhibitors of collagenase but not gelatinase reduce cartilage explant proteolglycan breakdown despite only low levels of matrix metalloproteinase activity. J Clin Pathol: Mol Pathol 49: M331–M339.
Brown, PD, Bloxidge, RE, Anderson, E & Howell, A (1993). Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11: 183–189.
Buo, L, Meling, GI, Karlsrud, TS, Johansen, HT & Aasen, AO (1995). Antigen levels of urokinase plasminogen activator and its receptor at the tumour–host interface of colorectal adenocarcinomas are related to aggressiveness. Human Pathol 26: 1133–1138.
Cawston, TE, Murphy, GM, Mercer, E, Galloway, WA, Hazleman, BL & Reynolds, JJ (1983). The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J 211: 313–318.
Clavel, C, Polette, M, Doco, M, Binninger, I & Birembaut, P (1992). Immunolocalisation of matrix metalloproteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 79: 261–270.
Cocoran, ML, Hewitt, RE, Kleiner, DE & Stetler-Stevenson, WG (1996). MMP-2: expression, activation and inhibition. Enzyme Protein 49: 7–19.
Conway, JG, Trexler, SJ, Wakefield, JA, Marron, BE, Emerson, DL, Bickett, DM, Deaton, DN, Garrison, D, Elder, M, McElory, A, Wilmott, N, Dockerty, AJP & McGeehan, GM (1996). Effect of matrix metalloproteinase inhibitors on tumour growth and spontaneous metastasis. Clin Exp Metastasis 14: 115–124.
Davies, B, Miles, DW, Happerfield, LC, Naylor, MS, Bobrow, LC, Rubens, RD & Balkwill, FR (1993). Activity of type IV collagenases in benign and malignant breast tissue. Br J Cancer 76: 1126–1131.
Duffy, MJ, Reilly, D, O’ Sullivan, C, O’Higgins, N & Fennelly, JJ (1990). Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335: 108–111.
Gallegos, NC, Smales, C, Savage, FJ, Hembry, RM & Boulos, PB (1995). The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 4: 111–119.
Grondahl-Hansen, J, Ralfkiaer, E, Kirkeby Kristensen, P, Lund, LT & Dano, K (1991). Localisation of urokinase type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138, (1) 111–117.
Hamdy, FC, Fadlon, EJ, Cottam, D, Lawry, J, Thurrell, W, Silcocks, PB, Anderson, JB, Williams, JL & Rees, RC (1994). Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69: 177–182.
Heppner, KJ, Matrisian, LM, Jensen, RA & Rodgers, WH (1996). Expression of most matrix metalloproteinase family members in breast cancer represents a tumour induced host response. Am J Pathol 149: 273–282.
Heussen, C & Dowdle, EB (1980). Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerised substrates. Anal Biochem 102: 196–202.
Hewitt, RE, Leach, IH, Powe, DG, Clark, IM, Cawston, TE & Turner, DR (1991). Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 49: 666–672.
Janicke, F, Schmitt, M & Graeff, H (1992). Clinical relevance of the urokinase-type plasminogen activators and their type I inhibitor in breast cancer. Semin Thromb Hemost 17: 303–312.
Janicke, F, Schmitt, M, Pache, L, Ulm, K, Harbeck, N, Hofler, H & Graeff, H (1993). Urokinase (uPA) and its inhibitor PAI-1 are strong prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24: 195–208.
Khokha, R, Martin, DC & Fata, JE (1995). Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Cancer Metastasis Rev 14: 97–111.
Knight, CG, Willenbrock, F & Murphy, G (1992). A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS 296: 263–266.
Kwaan, HC (1992). The plasminogen–plasmin system in malignancy. Cancer Metastasis Rev 11: 291–311.
Liabakk, NB, Talbot, I, Smith, RA, Wilkinson, K & Balkwill, F (1996). Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190–106.
Matrisian, LM, Wright, J, Newell, K & Witty, JP (1994). Matrix degrading metalloproteinases in tumour progression. Princess Takamatsu Symposia 24: 152–161.
Murray, GI, Duncan, ME, O’Neil, P, Melvin, WT & Fothergill, JE (1996). MMP-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461–462.
Parsons, SL, Watson, SA, Collins, HM, Griffin, NR, Clarke, PA & Steele, RJC (1998). Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 78: 1495–1502.
Polette, M, Clavel, C, Cockett, M, Girod-de-Bentzmann, S, Murphy, G & Birembaut, P (1993). Detection and localisation of mRNAs encoding matrix metalloproteinases and their tissue inhibitors in human breast pathology. Invasion Metastasis 13: 31–37.
Pyke, C, Kristensen, P, Ralfiaer, E, Grondahl-Hansen, J, Eriksen, J & Dano, K (1991). Urokinase-type plasminogen activator is expressed in stromal cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059–1067.
Remacle, AG, Noel, A, Duggan, C, McDermott, E, O’Higgins, N, Foidart, JM & Duffy, MJ (1998). Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77: 926–931.
Schmitt, M, Goretzki, L, Janicke, F, Calvette, J, Eulitz, M, Kbayashi, H, Chucholowski, N & Graeff, H (1991). Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50: 731–741.
Seftor, REB (1994). Electrophoretic analysis of proteins associated with tumour cell invasion. Electrophoresis 15: 454–462.
Stonelake, PS, Jones, CE, Neoptolemos, JP & Baker, PR (1997). Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 75: 951–959.
Taraboletti, G, Garofalo, A, Belotti, D, Drudis, T, Borsotti, P, Scanziani, E, Brown, PD & Giavazzi, R (1995). Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293–298.
Testa, JE & Quigley, JP (1990). The role of urokinase type plasminogen activator in aggressive tumour cell behaviour. Cancer Metastasis Rev 9: 353–367.
Torii, A, Kodera, Y, Uesaka, K, Hirai, T, Yasui, K, Morimoto, T, Yamamura, Y, Kato, T, Hayakawa, T, Fujimoto, N & Kito, T (1997). Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84: 133–136.
Yu, AE, Hewitt, RE, Connor, EW & Stetler Stevenson, WG (1997). Matrix metalloproteinases: novel targets for directed cancer therapy. Drugs Ageing 11: 229–244.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Garbett, E., Reed, M. & Brown, N. Proteolysis in human breast and colorectal cancer. Br J Cancer 81, 287–293 (1999). https://doi.org/10.1038/sj.bjc.6690689
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690689
Keywords
This article is cited by
-
Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer
British Journal of Cancer (2013)
-
Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test
British Journal of Cancer (2012)
-
Formulation and Characterization of Injectable Poly(dl-lactide-co-glycolide) Implants Loaded with N-Acetylcysteine, a MMP Inhibitor
Pharmaceutical Research (2008)
-
A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer
BMC Cancer (2006)
-
Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population
BMC Cancer (2006)